IBAB Ion Beam Applications SA

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES

Immediate Release – March 31st, 2025

Louvain-la-Neuve, Belgium, March 31st, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on March 24th, 2025.

Under this program, IBA has requested a financial intermediary to repurchase up to 650,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until December 31st, 2025, effective as from March 25th, 2025, to cover the company’s obligations under long-term incentive plans for management and certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 93,017 IBA shares on Euronext Brussels in the period from March 25th, 2025 up to and including March 31st, 2025, as follows:

        
 Trade dateShares purchasedAverage priceMin priceMax priceBuyback amount 
 25/03/20256,00011.62 €11.44 €11.70 €69,727.80 € 
 26/03/20257,00011.42 €11.36 €11.62 €79,967.30 € 
 27/03/20257,00011.30 €11.24 €11.40 €79,098.60 € 
 27/03/202558,01711.26 €11.26 €11.26 €653,271.42 € 
 28/03/20257,00011.24 €11.18 €11.38 €78,686.30 € 
 31/03/20258,00010.92 €10.88 €11.10 €87,349.60 € 
 TOTAL93,01711.27 €10.88 €11.70 €1,048,101.02 € 
        

These transactions include the purchase of a block of 58,017 shares at a price of 11.26 EUR/share, which was executed on March 27th, 2025 at 11:26:37 AM on the central order book of Euronext Brussels (XBRU).

The total number of shares purchased under this program therefore amounts to 93,017 since this is the first week of execution. As a result, the current situation with respect to treasury shares (held directly by IBA SA and indirectly through its subsidiary IBA Investments SRL) is the following :

      
   SharesVoting rights 
 IBA Investments SRL51,973103,946 
 IBA SA 406,596473,019 
 Total - Treasury shares458,569576,965 
 Total - Issued shares30,282,21840,514,366 
 Treasury shares in %1.51%1.42% 
      

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: -worldwide.com

Contact person

IBA

Thomas Pevenage,

Investor Relations

Attachment



EN
31/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Expect buoyed contribution from Private Banking. ASR: 1H: strong solvency, buyouts at 12% IRR. Deceuninck: Weak set of results, as expected following the change in CEO. EVS: Very weak 1H25, but guidance unchanged; convincing bolt-on deal in the US. IBA: IBA to install one P1 system at university campus in Heidelberg, Germany. NEPI Rockcastle: Robust performance, small upward revision to guidance

Guy Sips ... (+7)
  • Guy Sips
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
 PRESS RELEASE

Heidelberg University Hospital expands its particle therapy program wi...

Heidelberg University Hospital expands its particle therapy program with IBA’s Proteus®ONE solution Louvain-La-Neuve, Belgium, August 20, 2025 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer and Heidelberg University Hospital (Universitätsklinikum Heidelberg AöR, UKHD) announce today that they have signed a contract to install a Proteus®ONE1 compact proton therapy solution to be located on the University campus in Heidelberg, Germany. The first payment ...

 PRESS RELEASE

L'hôpital universitaire de Heidelberg élargit son programme de thérapi...

L'hôpital universitaire de Heidelberg élargit son programme de thérapie par particules avec une solution Proteus®ONE Louvain-la-Neuve, Belgique, le 20 août 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le traitement du cancer, et l'hôpital universitaire de Heidelberg (Universitätsklinikum Heidelberg AöR, UKHD) annoncent aujourd'hui la signature d'un contrat pour l'installation d'une solution compacte de protonthérapie Proteus®ONE1  sur le campus universitaire...

 PRESS RELEASE

IBA Notice of Half Year 2025 Results and Conference Call

IBA Notice of Half Year 2025 Results and Conference Call HY25 results webcast to take place on Thursday, 28 August 2025 at 3pm CEST Louvain-la-Neuve, Belgium, 07 August 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, announces today that it will publish its consolidated results for the half year 2025 on Thursday, 28 August 2025 at 7am CEST. Conference Call Information IBA’s management team will host team will host a conference call and webcast conducted in English to present the half year results, followed by a Q&A session. The con...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch